$JNJ bladder cancer drug Balversa can cause Hyperphosphatemia which $ARDX Tenapanor treats pending approval on Oct 17. Tenapanor will also be new SOC if approved. Tenapanor would be a nice addition to $JNJ 's long list of successful pharmaceutical products @Pharmdca@crypto_biotech@semodough